Prostate tissue androgens: history and current clinical relevance (Q37172910)

18 August 2017

1 reference

title

Prostate tissue androgens: history and current clinical relevance (English)

1 reference

18 August 2017

Leonard S Marks

1

1 reference

18 August 2017

Elahe A Mostaghel

series ordinal

2

1 reference

18 August 2017

Peter S Nelson

series ordinal

3

1 reference

18 August 2017

language of work or name

English

0 references

publication date

27 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

72

1 reference

18 August 2017

2

1 reference

18 August 2017

247-254

1 reference

Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The androgen axis in recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Immunoassay of endogenous plasma insulin in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Prostate concentrations of endogenous androgens by radioimmunoassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Racial differences in prostate androgen levels in men with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Androgen concentration in blacks with benign and malignant prostatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Prostatic tissue testosterone and dihydrotestosterone in African-American and white men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Simultaneous determination of testosterone, dihydrotestosterone and 5 alpha-androstan-3 alpha,-17 beta-diol by isotopic dilution mass spectrometry in plasma and prostatic tissue of patients affected by benign prostatic hyperplasia. Effects of 3-mont

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Changes in the endocrine environment of the human prostate transition zone with aging: simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Prevention of benign prostatic hyperplasia disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Risks of testosterone-replacement therapy and recommendations for monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Phosphorus-32 for intractable pain in carcinoma of prostate. Analysis of androgen priming, parathormone rebound, and combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Prostate cancer in men using testosterone supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Dihydrotestosterone measured in core biopsies from prostatic tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Determination of prostatic androgens in 10 mg of tissue using liquid chromatography-tandem mass spectrometry with charged derivatization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

Sex steroids in the umbilical circulation of fetal rhesus monkeys from the time of gonadal differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.03.033

The Intranuclear Binding of Testosterone and 5α-Androstan-17β-ol-3-one by Rat Prostate

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18502483

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18502483

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tissue selectivity of the anabolic steroid, 19-nor-4-androstenediol-3beta,17beta-diol in male Sprague Dawley rats: selective stimulation of muscle mass and bone mineral density relative to prostate mass

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18502483

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2008.03.033

1 reference

18 August 2017

0 references

1 reference